Details

Autor(en) / Beteiligte

• Ferrucci, Silvia
• Tavecchio, Simona
• Maronese, Carlo Alberto
• Balato, Anna
• Di Brizzi, Eugenia
• Ortoncelli, Michela
• Ribero, Simone
• Girolomoni, Giampiero
• Maurelli, Martina
• Belloni Fortina, Anna
• Caroppo, Francesca
• Naldi, Luigi
• Pezzolo, Elena
• Nettis, Eustachio
• Pugliese, Francesco
• Stingeni, Luca
• Hansel, Katharina
• Rubegni, Giovanni
• Calabrese, Laura
• Russo, Filomena
• Gola, Massimo
• Magnaterra, Elisabetta
• Rongioletti, Franco
• Mercuri, Santo Raffaele
• Paolino, Giovanni
• Savoia, Paola
• Veronese, Federica
• Foti, Caterina
• Ambrogio, Francesca
• Scalvenzi, Massimiliano
• Napolitano, Maddalena
• Patruno, Cataldo
• Dastoli, Stefano
• Corazza, Monica
• Borghi, Alessandro
• Calzavara-Pinton, Pier Giacomo
• Rossi, Mariateresa
• Offidani, Annamaria
• Radi, Giulia
• Bonzano, Laura
• Ferreli, Caterina
• Piras, Viviana
• Satta, Rosanna
• Sucato, Federica
• Malagoli, Piergiorgio
• Gaiani, Francesca
• Micali, Giuseppe
• Musumeci, Maria Letizia
• Fargnoli, Maria Concetta
• Esposito, Maria
• Grieco, Teresa
• Chello, Camilla
• Casazza, Giovanni
• Marzano, Angelo

Titel

Short-, mid- and long-term efficacy of dupilumab in moderate to severe atopic dermatitis: a real life multicenter Italian study on 2576 patients

Ist Teil von

• Clinical and experimental dermatology, 2024-06

Erscheinungsjahr

2024

Beschreibungen/Notizen

• BACKGROUNDThe efficacy and safety of dupilumab in atopic dermatitis (AD) have been defined in clinical trials but limited real-world evidence on long term treatment outcomes are currently available to inform clinical decisions.OBJECTIVESto describe long-term effectiveness and safety of dupilumab up to 48 months in patients with moderate-to-severe AD.METHODSa multicenter, retrospective, dynamic cohort study was conducted to assess long term effectiveness and safety of dupilumab in patients with moderate to severe AD in a real-world setting. Predictors of minimal disease activity (MDA) optimal treatment target criteria (defined as the simultaneous achievement of EASI90, itch NRS score ≤1, sleep NRS score ≤1 and DLQI ≤1) were investigated.RESULTS2576 patients were enrolled from June 2018 to July 2022. MDA optimal treatment target criteria were achieved by 506 (21.91%), 769 (40.63%), 628 (50.36%), 330 (55.37%) and 58 (54.72%) of those that reached 4, 12, 24, 36 and 48 months of follow-up, respectively. Logistic regression revealed a negative effect on MDA achievement for conjunctivitis and food allergy at all timepoints. Adverse events (AE) were mild and were observed in 373 (15.78%), 166 (7.02%), 83 (6.43%), 27 (4.50%) and 5 (4.55%) of those that reached 4, 12, 24, 36 and 48 months of follow-up. Conjunctivitis was the most frequently reported AE during the available follow-up. AE led to treatment discontinuation in <1% of patients during the evaluated time periods.CONCLUSIONHigh long-term effectiveness and safety of dupilumab were confirmed in this dynamic cohort of patients with moderate to severe AD, regardless of clinical phenotype and course at baseline. Further research will be needed to investigate the effect of Th2 comorbidities and disease duration on the response to dupilumab and other newer therapeutics for AD.